TrialBMJ open2024

Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials.

Vibeke Strand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.